JP2001515893A - 特定のベンゾチアジンジオキシドエンドセリンアンタゴニスト類およびその製造方法 - Google Patents

特定のベンゾチアジンジオキシドエンドセリンアンタゴニスト類およびその製造方法

Info

Publication number
JP2001515893A
JP2001515893A JP2000510724A JP2000510724A JP2001515893A JP 2001515893 A JP2001515893 A JP 2001515893A JP 2000510724 A JP2000510724 A JP 2000510724A JP 2000510724 A JP2000510724 A JP 2000510724A JP 2001515893 A JP2001515893 A JP 2001515893A
Authority
JP
Japan
Prior art keywords
benzo
phenyl
dihydro
dioxo
thiazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2000510724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001515893A5 (https=
Inventor
エイミ・メイ・バンカー
シュエ−ミン・チェン
アネット・メアリアン・ドウアティ
チターセ・リー
ジョウゼフ・トマス・リパイン
リチャード・スキーアン
ジェレミ・ジョン・エドマンズ
ジェラルド・デイヴィッド・カンター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of JP2001515893A publication Critical patent/JP2001515893A/ja
Publication of JP2001515893A5 publication Critical patent/JP2001515893A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2000510724A 1997-09-05 1998-08-13 特定のベンゾチアジンジオキシドエンドセリンアンタゴニスト類およびその製造方法 Abandoned JP2001515893A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5811197P 1997-09-05 1997-09-05
US60/058,111 1997-09-05
US9232698P 1998-07-09 1998-07-09
US60/092,326 1998-07-09
PCT/US1998/016856 WO1999012916A1 (en) 1997-09-05 1998-08-13 Certain benzothiazine dioxide endothelin antagonists and processes for their preparation

Publications (2)

Publication Number Publication Date
JP2001515893A true JP2001515893A (ja) 2001-09-25
JP2001515893A5 JP2001515893A5 (https=) 2006-02-16

Family

ID=26737251

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000510724A Abandoned JP2001515893A (ja) 1997-09-05 1998-08-13 特定のベンゾチアジンジオキシドエンドセリンアンタゴニスト類およびその製造方法

Country Status (24)

Country Link
US (5) US6265399B1 (https=)
EP (1) EP1009743B1 (https=)
JP (1) JP2001515893A (https=)
KR (1) KR20010023686A (https=)
AR (1) AR017056A1 (https=)
AT (1) ATE270281T1 (https=)
AU (1) AU759169B2 (https=)
BR (1) BR9812431A (https=)
CA (1) CA2296358A1 (https=)
CO (1) CO4970725A1 (https=)
DE (1) DE69824863T2 (https=)
ES (1) ES2221191T3 (https=)
HU (1) HUP0003689A3 (https=)
IL (1) IL134057A0 (https=)
IS (1) IS5356A (https=)
MY (1) MY116277A (https=)
NO (1) NO20001078L (https=)
NZ (1) NZ502670A (https=)
PE (1) PE116699A1 (https=)
PL (1) PL338983A1 (https=)
PT (1) PT1009743E (https=)
TW (1) TW508355B (https=)
UY (1) UY25168A1 (https=)
WO (1) WO1999012916A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509115A (ja) * 2004-08-03 2008-03-27 サノフイ−アベンテイス スルホンアミド誘導体、この調製およびこの治療用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU759169B2 (en) 1997-09-05 2003-04-10 Warner-Lambert Company Certain benzothiazine dioxide endothelin antagonists and processes for their preparation
EP1288199A4 (en) 2000-04-28 2005-10-12 Shionogi & Co INHIBITORS OF MMP-12
WO2001091736A2 (en) * 2000-05-31 2001-12-06 Warner-Lambert Company Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US20020115661A1 (en) * 2000-12-07 2002-08-22 Keller Laurence Harvey Method for treating chronic obstructive pulmonary disease
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
DE102008026894A1 (de) * 2008-06-05 2009-12-10 Evonik Degussa Gmbh Ink Jet Tinte
CA2969756A1 (en) * 2014-12-05 2016-06-09 Aquinnah Pharmaceuticals, Inc. Sulfonamide derivatives, compositions and methods of use in the treatment of neurodegenerative diseases
CN108727176B (zh) * 2018-07-26 2021-05-18 荆楚理工学院 一种制备5-卤-2,3-二羟基苯甲醛的方法
CN113214299A (zh) * 2021-03-01 2021-08-06 重庆西南制药二厂有限责任公司 γ-联苯双酯中间体及合成方法及γ-联苯双酯合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960856A (en) * 1975-06-20 1976-06-01 Warner-Lambert Company Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-dioxide
IN159273B (https=) * 1981-10-05 1987-04-25 Pfizer
JPH0495057A (ja) * 1990-08-08 1992-03-27 Taisho Pharmaceut Co Ltd Ｎ―置換スルホンアニリド化合物
AU675870B2 (en) * 1993-08-18 1997-02-20 Msd K.K. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5389620A (en) 1993-08-18 1995-02-14 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
CA2156849A1 (en) 1993-12-24 1995-07-06 Akira Mizuno Benzothiazine derivative
JPH0912562A (ja) 1995-06-22 1997-01-14 Suntory Ltd 置換ベンゾチアジン誘導体
US5482960A (en) 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
US5599811A (en) * 1995-02-21 1997-02-04 Warner-Lambert Company Benzothiazine dioxides as endothelin antagonists
CA2190708A1 (en) 1995-12-08 1997-06-09 Johannes Aebi Aminoalkyl substituted benzo-heterocyclic compounds
AU759169B2 (en) 1997-09-05 2003-04-10 Warner-Lambert Company Certain benzothiazine dioxide endothelin antagonists and processes for their preparation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509115A (ja) * 2004-08-03 2008-03-27 サノフイ−アベンテイス スルホンアミド誘導体、この調製およびこの治療用途

Also Published As

Publication number Publication date
AR017056A1 (es) 2001-08-22
PE116699A1 (es) 1999-12-19
HUP0003689A2 (hu) 2001-09-28
US20030073684A1 (en) 2003-04-17
DE69824863T2 (de) 2005-06-30
BR9812431A (pt) 2000-09-19
NO20001078D0 (no) 2000-03-02
US6440962B2 (en) 2002-08-27
US6265399B1 (en) 2001-07-24
UY25168A1 (es) 1999-05-14
MY116277A (en) 2003-12-31
US6252070B1 (en) 2001-06-26
ES2221191T3 (es) 2004-12-16
PL338983A1 (en) 2000-12-04
AU759169B2 (en) 2003-04-10
HUP0003689A3 (en) 2003-05-28
WO1999012916A1 (en) 1999-03-18
IS5356A (is) 2000-01-21
EP1009743A1 (en) 2000-06-21
IL134057A0 (en) 2001-04-30
US20020094980A1 (en) 2002-07-18
EP1009743B1 (en) 2004-06-30
DE69824863D1 (de) 2004-08-05
US6545150B2 (en) 2003-04-08
KR20010023686A (ko) 2001-03-26
CA2296358A1 (en) 1999-03-18
NO20001078L (no) 2000-03-02
AU9019698A (en) 1999-03-29
US20010036944A1 (en) 2001-11-01
PT1009743E (pt) 2004-09-30
TW508355B (en) 2002-11-01
CO4970725A1 (es) 2000-11-07
NZ502670A (en) 2003-01-31
ATE270281T1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
KR910007970B1 (ko) 4h-1-벤조피란-4-온 유도체 또는 이의 염, 이의 제조방법 및 활성 성분으로서 이를 함유하는 약제학적 조성물
AU688735B2 (en) Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
CN101772494A (zh) 4-嘧啶磺酰胺衍生物
JPH0714939B2 (ja) アンギオテンシンｉｉのアンタゴニストとしての置換ピラジノ［２，３−ｄピリミジノン類
JP2001515893A (ja) 特定のベンゾチアジンジオキシドエンドセリンアンタゴニスト類およびその製造方法
KR910008349B1 (ko) 벤조사이클로알칸 유도체를 제조하는 방법
BG62613B1 (bg) Бензотиазиндиоксиди като антагонисти на ендотелин
JP3040752B2 (ja) ２−（アリルフェニル）アミノ−イミダゾリン誘導体
EP0540400A1 (fr) Dérivés de quinoléine, utile comme angiotensine II antagonistes
EP0641302B1 (en) Alcohols as potassium channel openers and in treatment of urinary incontinence
JP2001515893A5 (https=)
EP0500409A1 (fr) Dérivés de 4-pyrimidinones, leur préparation et leur application en thérapeutique
KR20120007566A (ko) 기질 금속단백분해효소 억제제
KR20030041168A (ko) 비페닐 이속사졸 술폰아미드의 제조 방법
JP2003522770A (ja) ベンゾフランカルボキシアミドおよびそれらの治療的使用
JPH0662547B2 (ja) グリシン誘導体
MXPA00001091A (en) Certain benzothiazine dioxide endothelin antagonists and processes for their preparation
WO2017147893A1 (zh) 泊沙康唑、组合物、中间体及其制备方法和用途
EP0009487B1 (fr) Nouveaux derives de la benzamide
GB2337048A (en) Benzothiazine endothelin antagonists
CN109824537B (zh) 一种n-(3-乙酰基-2-羟基苯基)乙酰胺的制备方法
JP2001504816A (ja) ベンゾ［ｆ］キノリノンの合成
JPS63190879A (ja) カルボスチリル誘導体
JPWO1997011942A1 (ja) 新規スルホンアミド化合物および医薬組成物
JPH07215968A (ja) アゼラスチンの製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050812

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20060317